Sun Pharma Agrees to Acquire Checkpoint Therapeutics
The transaction includes Unloxcyt (cosibelimab-ipdl), which was approved by FDA in December 2024 for treatment of adults with cutaneous squamous cell carcinoma (cSCC).
https://www.pharmtech.com/view..../sun-pharma-acquire-
Discover the world at Altruu, The Discovery Engine